Olema Oncology (OLMA) Jefferies London Healthcare Conference 2025 summary
Event summary combining transcript, slides, and related documents.
Jefferies London Healthcare Conference 2025 summary
8 Jul, 2026Strategic focus and clinical pipeline
Emphasis on estrogen receptor positive, HER2 negative breast cancer, representing 70% of cases.
Lead asset palazestrant is a complete estrogen receptor antagonist in two pivotal phase III trials: OPERA-01 (2nd/3rd-line, monotherapy) and OPERA-02 (1st-line, in combination with ribociclib).
OPERA-01 readout expected in the second half of 2026; OPERA-02 readout anticipated for late 2028.
Additional asset OP3136, a KAT6 inhibitor, is in phase I trials for breast, prostate, and lung cancers, with first data expected late in the first half of 2026.
Competitive landscape and differentiation
Recent positive interim results from Roche's LIDARA trial in the adjuvant setting highlight the efficacy of next-generation SERDs in wild type ESR1, endocrine-sensitive populations.
Palazestrant distinguishes itself by enabling full dosing with multiple combination partners and maintaining high receptor occupancy.
Phase II data show palazestrant plus ribociclib achieves longer progression-free survival in both ESR1 mutant and wild type populations compared to competitors.
Market opportunity in 1st-line breast cancer is projected at $10–15 billion globally, with 2nd/3rd-line U.S. market at $5 billion.
Clinical trial design and regulatory considerations
OPERA-01 and OPERA-02 trials are powered to independently assess efficacy in both ESR1 mutant and wild type populations.
Success in OPERA-01 is defined as at least a two-month increase in progression-free survival, with unique potential to show monotherapy benefit in wild type patients.
Combination partner selection for OPERA-02 shifted to ribociclib due to its superior survival benefit and evolving standard of care.
Ongoing collaborations with Novartis (ribociclib) and Pfizer (atirmociclib) aim to extend palazestrant’s lifecycle and adapt to future standards.
Latest events from Olema Oncology
- Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026